Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2823 (LINC02823) is a member of the long non-coding RNA (lncRNA) family, specifically classified as a lincRNA, which are RNA transcripts longer than 200 nucleotides that do not overlap with protein-coding genes[1][5]. LincRNAs are known to participate in various aspects of gene regulation, such as modulating chromatin accessibility and fine-tuning gene expression, although the precise cellular function of the majority of lincRNAs, including LINC02823, remains poorly characterized[3][5]. There is currently no evidence that LINC02823 acts as a direct therapeutic target, nor is there data linking it to specific diseases or drug interactions in the available sources[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2823 (LINC02823).